In yesterday’s Wall Street session, Revance Therapeutics Inc (NASDAQ:RVNC) shares traded at $3.08, up 0.33% from the previous session.
RVNC stock price is now -28.10% away from the 50-day moving average and -28.94% away from the 200-day moving average. The market capitalization of the company currently stands at $319.44M.
With the price target reduced from $16 to $9, Mizuho Downgraded its rating from Buy to Neutral for Revance Therapeutics Inc (NASDAQ: RVNC). On January 09, 2024, Goldman Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $30 to quote $8, while ‘Exane BNP Paribas’ rates the stock as ‘Neutral’
In other news, Hollander David, CMO & Global Therapeutics Lead sold 3,908 shares of the company’s stock on Nov 18 ’24. The stock was sold for $16,296 at an average price of $4.17. Upon completion of the transaction, the CMO & Global Therapeutics Lead now directly owns 104,945 shares in the company, valued at $0.32 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 16 ’24, Chief Commercial Officer Jordan Erica sold 2,392 shares of the business’s stock. A total of $9,096 was realized by selling the stock at an average price of $3.80. This leaves the insider owning 114,864 shares of the company worth $0.35 million. A total of 8.71% of the company’s stock is owned by insiders.
During the past 12 months, Revance Therapeutics Inc has had a low of $2.30 and a high of $9.74. The fifty day moving average price for RVNC is $4.3251 and a two-hundred day moving average price translates $4.3506 for the stock.
The latest earnings results from Revance Therapeutics Inc (NASDAQ: RVNC) was released for 2024-09-30. The net profit margin was -74.67% and return on equity was -2096.78% for RVNC. The company reported revenue of $59.88 million for the quarter, compared to $54.11 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 10.66 percent.
